Augmenta Bioworks is obtaining the antiviral antibody sequences from the blood of those who had COVID-19 but recovered. With this, they are scaling into a therapeutic which could be dosed into patients by fall.
Augmenta Bioworks is obtaining the antiviral antibody sequences from the blood of those who had COVID-19 but recovered. With this, they are scaling into a therapeutic which could be dosed into patients by fall.